Abstracts tagged "monoclonal antibodies and vasculitis"

Abstract Number: 1756 • 2018 ACR/ARHP Annual Meeting
Systematic Review of the Clinical Effectiveness of Treatments in Eosinophilic Granulomatosis with Polyangiitis
Scott Doyle¹, Annete Njue², Matthew Lyall², Rebecca Rushton², Anne Heyes² and Maebh Kelly³, ¹Value Evidence and Outcomes, GlaxoSmithKline, London, United Kingdom, ²RTI Health Solutions, Manchester, United Kingdom, ³Pope Woodhead, London, United Kingdom
Background/Purpose: To better understand the available clinical effectiveness data in eosinophilic granulomatosis with polyangiitis (EGPA), a systematic literature review was undertaken. The primary objective of…
Abstract Number: 1757 • 2018 ACR/ARHP Annual Meeting
An Economic Systematic Literature Review of Eosinophilic Granulomatosis with Polyangiitis
Scott Doyle¹, Emily Moss², Louise Hartley², Chris Knight², Judith Bell², Outi Ahdesmäki² and Maebh Kelly³, ¹Value Evidence and Outcomes, GlaxoSmithKline, London, United Kingdom, ²RTI Health Solutions, Manchester, United Kingdom, ³Pope Woodhead, London, United Kingdom
Background/Purpose: To better understand the available economic evaluations in eosinophilic granulomatosis with polyangiitis (EGPA), a systematic literature review was undertaken. The primary objective of this…
Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting
Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Bertrand Lioger^1,2, Fanny Hennekinne¹, Marie-Sara Agier³, Annie-Pierre Jonville-Bera^3,4 and François Maillot^1,5, ¹Internal Medicine, Tours University Hospital, Tours, France, ²GICC UMR 7292, University François Rabelais, Tours, France, ³Clinical Pharmacology, Tours University Hospital, Tours, France, ⁴Regional Pharmacovigilance Center, Tours University Hospital, Tours, France, ⁵INSERM U1069, University François Rabelais, Tours, France
Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].